SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Amgen Inc. (AMGN)
An SI Board Since December 1996
Posts SubjectMarks Bans Symbol
1906 112 0 AMGN
Emcee:  trevor john wilkinson Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
1156shouldn't have much affect; patent near expiration and anesp taking the placJGoren-10/23/2004
1155-X Thanks for posting that. Is the rest of the book of that quality?keokalani'nui-10/22/2004
1154Anyone have an opinion of the long term effect of British court overturning Amgesteve kammerer-10/22/2004
1153from Morningstar: Amgen's AMGN third-quarter earnings released Wednesday aftmopgcw-10/21/2004
1152A very nice summary of EPO patent and its history biopharma.com by <b>RonXpiderman-10/17/2004
1151for GS, it is the view of the sector as a whole based on the historical fundamenmopgcw-10/14/2004
1150mopgc- What is "coverage view"? TIA, LarryLiatris Spicata-10/14/2004
1149GS: AMGN (OP/N): Minimal impact from change of Remicade label JNJ updated the Remopgcw-10/14/2004
1148GS: We maintain our Outperform rating based on solid sales and EPS growth, an inmopgcw-10/14/2004
1147Leg: AMGN :Amgen's Analyst Meeting; AMG 162 Data In Line with Expectations mopgcw-10/12/2004
1146Alas we have a dearth of oncologists posting on SI. But from what I have read, Biomaven-10/6/2004
1145Seems odd to me that several analysts are expecting close to zero sales for palif_mcknuckles-10/6/2004
1144GS: Amgen Inc. EPS (FY Dec) 2004E $2.40, 2005E $2.85 Outperform/Neutral (AMGN) $mopgcw-10/4/2004
1143GS: AMGN (OP/N): Weekly Syringe & expanded label for Enbrel - minor positivemopgcw-9/29/2004
1142GS: AMGN (OP/N): Upbeat presentation on improving pipeline 52-Week Range US$67-mopgcw-9/29/2004
1141The ASN abstracts are available online, including three from Fibrogen. They are Biomaven-9/28/2004
1140my understanding is they are currently enrolling the P2 for that one, dont know mopgcw-9/27/2004
1139Noticed somewhere that amgn is about to run a CHF/anemia trial using aranesp andkeokalani'nui-9/27/2004
1138GS: AMGN (OP/N): Unwarranted concerns on competitor to Epogen 52-Week Range US$mopgcw-9/27/2004
1137thanks for the postJGoren-9/23/2004
1136SSB: AMGN: Positive 12-Month Data for AMG 162 in Osteoporosis at ACR Septemmopgcw-9/16/2004
1135Just looked at the AMGN (which I do not own) chart. I have no idea what's gotom pope-9/13/2004
1134GS: Sep 13, 2004 AMGN (OP/N): Weakness on concerns about timing of 2005 guidancemopgcw-9/13/2004
1133From a current perspective it seems much more likely the stock will move lower fdavidtrx-7/31/2004
1132AMGN (OP/N):FIRST TAKE on ASP. Reduction inline but disruption in usage may occmopgcw-7/27/2004
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News